6 / 31
H2H studies of anti-EGFR vs anti-VEGF in 1
st
-line mCRC
1. Heinemann et al. Lancet Oncol 2014 2. Schwatzberg et al. J Clin Oncol 2014. 3. Lenz et al. Ann Oncol 2014; 25 (supppl 5): 438-13.
PEAK
2
FIRE-3
1
CALGB 80405
3
Sponsors/
Collaborators
Amgen
University of Munich –
Klinikum Grosshadern Merck
Cancer and Leukaemia Group B
National Cancer Institute (NCI)
Trial
design
Phase II, randomized,
Phase III, randomized
Phase III, randomized
Number of
patients
285
592
2283
population
Untreated KRASwt mCRC
Untreated KRASwt mCRC
Untreated KRASwt mCRC
Primary
endpoint
Progression free survival
(PFS)
Overall response rate
(ORR)
Overall survival
(OS)
Secondary
endpoints
OS, ORR, safety
PFS, OS, resection rate, and
safety
PFS, ORR, resection rate, and
safety
Chemotherapy
partner
FOLFOX
FOLFIRI
FOLFOX or FOLFIRI